Docoh
Loading...

SBBP Strongbridge Biopharma

APP
Utility
Methods and Compositions for Treating Diabetes, Metabolic Syndrome and Other Conditions
30 Sep 21
Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Per Marin
Filed: 10 Nov 20
APP
Utility
Compositions and Methods of Use
23 Sep 21
Provided is a pharmaceutical composition comprising: (a) granules comprising an active pharmaceutical ingredient, and one or more intragranular excipients; and an extragranular portion comprising at least one release modifier.
Fredric Jay COHEN
Filed: 18 Jan 21
APP
Utility
Methods of Treating Disease with Levoketoconazole
2 Sep 21
Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.
Fredric COHEN
Filed: 13 May 21
APP
Utility
Methods of Treating Disease with Dichlorphenamide
22 Jul 21
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
Fredric Jay COHEN
Filed: 29 Mar 21
GRANT
Utility
Methods of treating disease with levoketoconazole
1 Jun 21
Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.
Fredric Cohen
Filed: 2 Sep 20
GRANT
Utility
Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
27 Apr 21
The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions.
Michel Afargan
Filed: 16 Jul 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
8 Apr 21
Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is being administered an organic anion transporter-1 (OAT1) inhibitor and/or an organic anion transporter-3 (OAT3) inhibitor to treat an associated disease or disorder.
Fredric Jay COHEN
Filed: 16 Dec 20
APP
Utility
Methods of Treating Disease with Dichlorphenamide
18 Mar 21
Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate to treat an associated disease or disorder.
Fredric Jay COHEN
Filed: 1 Dec 20
APP
Utility
Methods of Treating Disease with Levoketoconazole
23 Dec 20
Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.
Fredric COHEN
Filed: 1 Sep 20
GRANT
Utility
Methods and compositions for treating diabetes, metabolic syndrome and other conditions
16 Nov 20
Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Per Marin
Filed: 15 Dec 19
APP
Utility
Methods and Compositions for the Treatment of Cushing's Syndrome Using 2S, 4R Ketoconazole
21 Oct 20
Methods for treating Cushing's Syndrome and other conditions associated with excessive cortisol production such as Cushing's Disease, ectopic adrenocorticotropic hormone secretion, ectopic corticotropin-releasing hormone secretion, adrenal-dependent Cushing's Syndrome, adrenal adenoma, adrenal autonomy, or any other condition associated with persistent or recurrent endogenous hypercortisolemia are provided.
Theodore Richard Koziol
Filed: 28 Jun 20
APP
Utility
Methods and Compositions for Treating Diabetes, Metabolic Syndrome and Other Conditions
19 Aug 20
Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Per Marin
Filed: 15 Dec 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
22 Jul 20
Provided herein is a method for treating primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Fredric Jay COHEN
Filed: 21 Jan 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
22 Jul 20
Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) inhibitor and/or an organic anion transporter-3 (OAT3) inhibitor.
Fredric Jay COHEN
Filed: 21 Jan 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
22 Jul 20
Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) inhibitor and/or an organic anion transporter-3 (OAT3) inhibitor.
Fredric Jay COHEN
Filed: 7 Aug 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
3 Jun 20
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
Fredric Jay COHEN
Filed: 29 Nov 18
APP
Utility
Methods of Treating Disease with Dichlorphenamide
3 Jun 20
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
Fredric Jay COHEN
Filed: 13 Aug 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
3 Jun 20
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
Fredric Jay COHEN
Filed: 13 Aug 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
3 Jun 20
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
Fredric Jay COHEN
Filed: 13 Aug 19
APP
Utility
Methods of Treating Disease with Dichlorphenamide
3 Jun 20
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof.
Fredric Jay COHEN
Filed: 13 Aug 19
Patents are sorted by USPTO publication date, most recent first